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Abstract
A young man with subacute neuronopathy
following tetracycline treatment is described.
The symptoms started as a sensory dorsal root
affection  but  by  time  also  involved  motor
nerves. He developed a severe sensory ataxia
with pseudoathetotic movements. Other possi-
ble aetiologies were scrutinized and excluded.
Tetracycline induced neuronopathy is hitherto
not reported in the literature. We propose a
possible association between treatment with
tetracycline  and  the  development  of  sensory
neuronopathy in this patient.
Introduction
Sensory  neuropathy  has  been  reported  in
patients treated with other antibiotics e.g.peni-
cillin  or  a  semisynthetic  derivate,1 chloram-
phenicol,2 and metronidazole.3 Nitrofurantoin
treatment has caused sensory-motor neuropa-
thy4 and dapsone treatment has caused motor
neuropathy.5 A  topical  tetracycline  induced
neuritis has been reported in one patient,6 oth-
erwise no reports of an association between
neuropathy  and  orally  taken  tetracycline  has
been published, to our knowledge.
Case Report
This  25-year  old  previously  healthy  man
with  no  hereditary  neuromuscular  diseases
experienced  paresthesias  in  the  whole  body
except the face two weeks after starting tetra-
cycline treatment (100 mg daily, p.o.) because
of acne. He stopped taking tetracycline after
two months. When examined 4 months after
the debut of symptoms he also complained of
clumsiness  in  hands  and  feet.  Examination
revealed  absent  reflexes  and  a  marked
decrease in position sense and elevated vibra-
tory thresholds in hands and feet. The gait was
slightly ataxic. Testing for touch, cold and pin-
prick sensation were intact throughout. Motor
power was normal. Blood tests including cobal-
amine,  folic  acid,  thyroxine,  plasma-elec-
trophoresis, fasting-glucose, creatinine, liver-
enzymes, anti-nuclear antibodies (ANA includ-
ing SS-A and SS-B) and HIV-test were normal.
Cerebrospinal  fluid  (CSF)  analysis  revealed
normal  white  cell  count,  albumin-ratio,  IgG-
index and no oligoclonal bands. Serology for
Borrelia was normal in the CSF and peripheral
blood.  Nerve  conduction  study  results  were
normal including sensory nerve testing (Table
1)  as  was  the  electromyography  (EMG).
Sensory evoked potentials (SEP) were, howev-
er, not elictable from the right median and tib-
ial nerve and were of low amplitude from the
left side. Quantitative sensory testing (QST)
showed a marked decrease in vibratory sensi-
bility in all extremities and a slight decrease in
touch  and  temperature  sensibility  in  the
hands. Magnetic resonance imaging (MRI) of
the  brain  and  cervical  spine  was  normal.
Biopsy of the sural nerve showed a slight loss
of finecaliber myelinated sensory nerve fibers
but  no  inflammation.  Muscle  biopsy  of  the
anterior tibial muscle was normal. Treatment
with  high-dose  intravenous  steroids  did  not
have any effect on the condition. His symp-
toms continued to worsen and on examination
one year after the debut he showed a marked
sensory  ataxia  with  pseudoathetotic  move-
ments. Position sense and vibratory thresholds
were unobtainable from hands and feet. Touch
and  pinprick  sensibility  were  markedly
decreased in the hands and absent in the feet.
Muscle  power  was  slightly  decreased  in  the
hands but was otherwise normal. Nerve con-
duction studies 26 months after debut of symp-
toms showed decreased motor velocities and
decreasing amplitudes in the median nerves
and prolonged F-wave latencies in all nerves
except the left peroneal. Sensory results were
still normal (Table 1). EMG showed denerva-
tion potentials in the right tibial, left vastus
and in the left dorsal interosseus muscle and
decreased interference pattern in all muscles.
SEP in the median and tibial nerves bilaterally
did not give any reproducible responses. On
clinical examination eight years after the ini-
tial  symptoms  he  could  walk  5  meters  with
help. He showed muscle atrophies in the arms
and legs, absent vibratory thresholds through-
out the body, areflexia, and decreased touch
and pin-prick sensibility in the arms, legs and
in  the  distribution  of  the  trigeminal  nerve.
During the last year his symptoms had been
fairly  stable  and  muscle  strength  even
increased in hands and feet.
Discussion
Our patient resembles the cases described
by Sternman et al.1 because of relative rapid
development of profound sensory loss, ataxia
and areflexia. After some time he also devel-
oped slight motor weakness in the upper limbs.
Electrophysiological  investigation  including
neurography, EMG and SEP and nerve-biopsy
indicated that the lesion was most prominent
in the dorsal and by time also ventral nerve
roots. These findings are in agreement with
those found in patients treated with nitrofu-
rantoin  in  which  the  investigators  found
degeneration  of  posterior  and  to  a  lesser
degree anterior nerve roots and ganglion cells
on post-mortem examination.7 There was no
recovery and the patient experienced great dif-
ficulty in proprioceptive tasks. The pronounced
decrease  in  position  sensibility  points  to  a
damage of the sensory nerve roots compatible
with  a  toxic  neuronopathy.  Toxic  causes  of
neuronopathy have previously been described.8
We found dissociation between relatively pre-
served neurography results and by time com-
pletely absent SEP responses in arms and legs,
also  pointing  towards  a  sensory  dorsal  root
injury. On the third nerve conduction investi-
gation we found prolonged F-wave latencies in
all except one nerve indicating also a proximal
motor  nerve  root  involvement.  Motor  nerve
roots  may  be  more  resistant  to  toxic  agents
than the dorsal root ganglia. The dorsal root
ganglion  cells  are  vulnerable  to  exogenous
agents as the blood-brain barrier is incomplete
at these sites. This would explain why toxic
agents  i.e. doxorubicin  and  pyridoxine  are
especially toxic to dorsal root ganglion cells.
There was no occult neoplasm on follow-up, we
found no MAG-reactive monoclonal gammopa-
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Sjögren´s syndrome and there was no preced-
ing  infection  as  has  been  reported  in  cases
with sensory neuronopathy.9,10 Our patient ful-
fils the criteria for probable neuronopathy as
proposed by Camdessanché et al.11
Several  factors  are  suggestive  of  a  toxic
effect of tetracycline on the peripheral nervous
system in our patient. There is a time associa-
tion  between  development  of  neuronopathy
and  the  tetracycline  treatment.  No  obvious
other  cause  of  the  neuronopathy  was  found
despite  extensive  evaluation.  He  is  a  young
man, usually not prone to develop neuropathy
if  hereditary  causes  and  the  Guillain-Barré
syndrome are excluded. This patient had no
family history of neuromuscular disorders and
no clinical or laboratory findings supportive of
the  Guillain-Barré  syndrome.  After  several
years of worsening the condition seemed to
stabilize  and  even  improve  concerning  his
muscle  strength.  An  immunological  reaction
against dorsal nerve roots elicited by tetracy-
cline cannot be ruled out, however. A few case
reports on neuropathy as an adverse event of
minocycline (a synthetic tetracycline antibiot-
ic) treatment have been published; one ulnar
neuropathy, one carpal tunnel syndrome, one
vasculitic neuropathy and one axonal sensory
neuropathy.12-15 The case described by Graham
and Bell14 presents a 16-year-old girl develop-
ing acute polyarthritis and a peripheral neu-
ropathy  after  taking  minocycline  because  of
acne, in part resembling our patient. In the
World Health Organization (WHO) register of
Global Individual Case Safety Report (ICSR)
database,  VigiBase  (www.who-umc.org)  of
adverse  drug  reactions  (ADR),  there  are  15
reports  of  neuropathy  in  association  with
tetracycline  treatment  (11  peripheral  neu-
ropathies, one of which was sensory in type, 3
neuritis  and  one  nerve  compression).  The
occurrence of neuropathy in association with
tetracycline treatment must be rare bearing in
mind that only a few medical case reports have
been published, to our knowledge. In experi-
mental studies on rat sciatic nerves minocy-
cline was shown to have an inhibiting effect on
regeneration of peripheral nerves, also impli-
cating an impact of constructive events after
nerve injury.16 In conclusion we propose a pos-
sible  association  between  treatment  with
tetracycline  and  the  development  of  sensory
neuronopathy in this patient.
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Table 1. Neurography findings in the patient with possible tetracycline induced neuronopathy.
CV Amp DL F-w CV Amp DL F-w CV Amp DL F-w
Investigation done
after debut 
of symptoms 4 months 14 months 26 months
Motor nerves
Median dx 55 18 3.1 ND 52 9 3.3 ND 41* 4 3.8 56*
Median sin 57 14 3.2 ND 52 9 3.1 ND 44 6 3.6 42*
Ulnar dx ND ND ND ND ND ND ND ND 52 11 3.0 32*
Ulnar sin ND ND ND ND ND ND ND ND 51 10 3.1 NR*
Peroneal dx 45 14 4.0 ND 44 13 4.2 ND 39 8 4.5 61*
Peroneal sin 46 12 4.8 ND 48 13 4.9 ND 41 5 4.9 49
Sensory nerves
Median dx 59 12 2.5 - 54 12 2.8 - 62 7 ND
Median sin 55 12 2.6 - 53 12 2.8 - 58 10 ND
UInar dx ND ND ND - ND ND ND - 51 7 ND
Ulnar sin ND ND ND - ND ND ND - 57 7 ND
Sural dx 41 5 3.8 - 42 6 3.2 - 40 5 ND
Sural sin 43 6 3.3 - ND ND NDa - NR* NR* NRa*
ND, Not Done; NR, No Response; CV, conduction velocity (m/sec); Amp, amplitude (motor nerves in mV and in sensory nerves in μV); DL, distal latency (msec); F-w, F-wave (msec).  a. Nerve biopsy was performed on
the left sural nerve. *NR and mean values ±2SD.